Associated Papers
Loss of HES1 Expression is Associated with Extracellular Matrix Remodeling and Tumor Immune Suppression in KRAS Mutant Colon Adenocarcinomas.
Wang L et al.
Research Square, 2023
Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC.
Cooper AJ et al.
Jto Clinical and Research Reports, 2022
36118132 (PubMed )
Supplement: mmc2.docx
Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
Zhong F et al.
Cancer Medicine, 2019
The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.
Zhang Y et al.
Journal for Immunotherapy of Cancer, 2019
30944026 (PubMed )
Supplement: 40425_2019_581_MOESM3_ESM.pdf
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.
Windon AL et al.
Journal of Gastrointestinal Oncology, 2018
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.
Kato S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
27683183 (PubMed )
Supplement: 10780432ccr161679-sup-168576_1_supp_3636667_wcc1ns.docx
Select a paper to view details